A Phase II Study of PEP02 as a Second Line Therapy for Patients With Metastatic Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2014
At a glance
- Drugs Irinotecan (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors PharmaEngine
- 10 Jun 2017 Biomarkers information updated
- 22 Aug 2013 Results have been published in the British Journal of Cancer, according to a Merrimack Pharmaceuticals media release.
- 13 May 2013 Merrimack expects to report results from this trial in the second half of 2013.